TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12537040

Group type: EXPERIMENTAL
Intervention: Family intervention for schizophrenia
Number of subjects: 79
Study: 10781640

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen (n=15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 5 mg simvastatin (n=15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination therapy (n=15)
Number of subjects: 45
Study: 8782136

Group type: EXPERIMENTAL
Intervention: Intraarticular local anesthetic (bupivacaine 0.25%, 5 ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1460156

Group type: EXPERIMENTAL
Intervention: Skills training counseling
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Support counseling
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Rapid smoking
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Skills training
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Self-reports of pretreatment craving
Number of subjects: 126
Study: 2937131

Group type: EXPERIMENTAL
Intervention: Intramuscular medroxyprogesterone acetate (MPA) 500 mg/day for at least two months after the operation
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: MPA 500 mg/3 times a week for one year
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 165
Study: 29846031

Group type: EXPERIMENTAL
Intervention: Pharmacy-based intervention including medication review, regular dose dispensing, and counselling regarding medication use and symptoms of heart failure.
Number of subjects: 248

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Pharmacy-based intervention.
Number of subjects: 248
Study: 26916877

Group type: EXPERIMENTAL
Intervention: Daily Teriparatide (TPTD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclic Teriparatide (TPTD)
Number of subjects: 0
Study: 24866985

Group type: EXPERIMENTAL
Intervention: Fetal Alcohol Spectrum Disorder (FASD) knowledge survey
Number of subjects: 1035

Group type: COMPARATOR
Intervention: Comparison with healthcare professionals
Number of subjects: 1035
Study: 22802603

Group type: EXPERIMENTAL
Intervention: Phototherapy at 20 cm distance from the device
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Phototherapy at 29 cm distance from the device
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Phototherapy at 38 cm distance from the device
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Phototherapy at 47 cm distance from the device
Number of subjects: 151
Study: 21034479

Group type: EXPERIMENTAL
Intervention: Pro-active multi-component nurse-led transitional care program (including a handover moment with a community care Care Nurse during hospital admission and five home visits after discharge)
Number of subjects: 674

Group type: COMPARATOR
Intervention: Care as usual after discharge
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Pro-active multi-component nurse-led transitional care program
Number of subjects: 674
Study: 18687376

Group type: EXPERIMENTAL
Intervention: Dopamine D2 receptor (DRD2) 957C>T polymorphism
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group (subjects without substance dependence)
Number of subjects: 238
Study: 16162624

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 20

Group type: COMPARATOR
Intervention: No ACE inhibitors
Number of subjects: 20
Study: 12236448

Group type: EXPERIMENTAL
Intervention: TTA lifting from 30 cm and knee height
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: TFA lifting from knee and thigh height
Number of subjects: 8

Group type: COMPARATOR
Intervention: Able-bodied controls lifting from all three heights
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: TTA and TFA lifting mechanics
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: TTA stability
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: TFA stability
Number of subjects: 8
Study: 9951573

Group type: EXPERIMENTAL
Intervention: Ondansetron pretreatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7759412

Group type: EXPERIMENTAL
Intervention: 1 mg/kg of ketoprofen
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline placebo (control)
Number of subjects: 12
Study: 2106841

Group type: EXPERIMENTAL
Intervention: Quadrantectomy, axillary dissection, and radiotherapy (QUART)
Number of subjects: 1232
Study: 232024

Group type: EXPERIMENTAL
Intervention: Saralasin
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Converting enzyme inhibitors SQ 20881 and captopril
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Saralasin, SQ 20881, and captopril
Number of subjects: 44

Group type: COMPARATOR
Intervention: Prior sodium depletion
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Angiotensin blockade
Number of subjects: 44
Study: 30290037

Group type: EXPERIMENTAL
Intervention: rTMS at 10 Hz (high frequency) and 1 Hz (low frequency) targeting the PCC and precuneus
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 20
Study: 30054634

Group type: EXPERIMENTAL
Intervention: Lay Health Worker intervention (6-month program)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Lay Health Worker intervention (30 days before death)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 213
Study: 26248655

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (InGaAlP laser, 650 nm, 100 mW, 2 J per point, applied from the first day of conditioning until D + 5)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham group (simulated laser treatment)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 35
Study: 24076059

Group type: EXPERIMENTAL
Intervention: Low-FODMAP diet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Australian diet
Number of subjects: 30
Study: 21586498

Group type: EXPERIMENTAL
Intervention: Music therapy for 30 min each morning for 11 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 24
Study: 19823189

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (TLP)
Number of subjects: 704

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 704

Group type: COMPARATOR
Intervention: Metformin plus rosiglitazone
Number of subjects: 704
Study: 17023095

Group type: EXPERIMENTAL
Intervention: 9-valent conjugate pneumococcal vaccine
Number of subjects: 0
Study: 15901744

Group type: EXPERIMENTAL
Intervention: Eniporide (2.5-400 mg)
Number of subjects: 457
Study: 12612018

Group type: EXPERIMENTAL
Intervention: Electrically induced blinking
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Spontaneous blinking
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Air puff induced blinking
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Eye position at 30 degrees above horizontal
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Eye position at 30 degrees below horizontal
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Integrated OO‐EMG
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Average blinking data
Number of subjects: 4
Study: 10480777

Group type: EXPERIMENTAL
Intervention: Intensive therapy (IT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nondiabetic children
Number of subjects: 25
Study: 8726832

Group type: EXPERIMENTAL
Intervention: Secretin
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Secretin (in cirrhotic patients)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo (in cirrhotic patients)
Number of subjects: 69
Study: 1766125

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 20 micrograms.kg‐1
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 40 micrograms.kg‐1
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 137
Study: 6351027

Group type: EXPERIMENTAL
Intervention: Erythrityl tetranitrate (ETN) 5 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 5 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31957168

Group type: EXPERIMENTAL
Intervention: SkinUp® Beauty Device
Number of subjects: 20

Group type: COMPARATOR
Intervention: Corneometer® CM825
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SkinUp® Beauty Device and Corneometer® CM825
Number of subjects: 20
Study: 30616791

Group type: EXPERIMENTAL
Intervention: Primary radiotherapy (RT)
Number of subjects: 2754

Group type: COMPARATOR
Intervention: Primary surgery (PS)
Number of subjects: 2754

Group type: EXPERIMENTAL
Intervention: Primary radiotherapy with concurrent chemotherapy (CRT)
Number of subjects: 2754

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy with definitive RT
Number of subjects: 2754
Study: 28471697

Group type: EXPERIMENTAL
Intervention: Pirfenidone 2,403 mg/d
Number of subjects: 1247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1247
Study: 26402363

Group type: EXPERIMENTAL
Intervention: Telephone-based care management intervention
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 136
Study: 23431120

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delayed enteral nutrition (DEN)
Number of subjects: 60
Study: 21177517

Group type: EXPERIMENTAL
Intervention: Acceptance-based behavior therapy (ABBT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cognitive therapy (CT)
Number of subjects: 16
Study: 20137430

Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin (one-day group)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 0.3% levofloxacin (one-day group)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 0.3% tobramycin (one-day group)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin (three-day group)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 0.3% levofloxacin (three-day group)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 0.3% tobramycin (three-day group)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: PVI irrigation (one-day group)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: PVI irrigation (three-day group)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Levofloxacin sensitivity (G(+)C)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Levofloxacin sensitivity (G(-)B)
Number of subjects: 135
Study: 17725542

Group type: EXPERIMENTAL
Intervention: ALA group (20 mg/kg body weight of 5-aminolevulinic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: White-light group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ALA group
Number of subjects: 0
Study: 15212625

Group type: EXPERIMENTAL
Intervention: Ziconotide
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 10975044

Group type: EXPERIMENTAL
Intervention: Multi-injection protocol for correcting postprandial blood glucose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postprandial blood glucose management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postprandial blood glucose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OGTT 2 h blood glucose
Number of subjects: 0
Study: 8869411

Group type: EXPERIMENTAL
Intervention: Isotonic saline (50 ml/kg for 1 h) in acute study
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High salt intake (260 mmol/day) in chronic study
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low salt intake (30 mmol/day) in chronic study
Number of subjects: 60
Study: 1948810

Group type: EXPERIMENTAL
Intervention: RU 28318 (160 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Spironolactone (80 mg)
Number of subjects: 80
Study: 6394759

Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: sulindac
Number of subjects: 10
Study: 31288186

Group type: EXPERIMENTAL
Intervention: Post-LLETZ satisfactory colposcopy
Number of subjects: 601

Group type: COMPARATOR
Intervention: Parity
Number of subjects: 601

Group type: COMPARATOR
Intervention: Depth of LLETZ specimen
Number of subjects: 601

Group type: COMPARATOR
Intervention: Age
Number of subjects: 601

Group type: COMPARATOR
Intervention: Pre-LLETZ colposcopy results
Number of subjects: 601
Study: 29403268

Group type: EXPERIMENTAL
Intervention: 80 mg triamcinolone (2 mL) and 1 mL of 2% lidocaine
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone (1 mL), 1 mL of 2% lidocaine, and 1 mL normal saline
Number of subjects: 161

Group type: COMPARATOR
Intervention: 1 mL of 2% lidocaine and 2 mL normal saline
Number of subjects: 161
Study: 26979830

Group type: EXPERIMENTAL
Intervention: Filorexant 2.5mg
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Filorexant 5mg
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Filorexant 10mg
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Filorexant 20mg
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study: 21833684

Group type: EXPERIMENTAL
Intervention: Shoulder manipulation and arthroscopic arthrolysis (Group A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Glenohumeral steroid injections (Group B)
Number of subjects: 44
Study: 20587725

Group type: EXPERIMENTAL
Intervention: Hypoglycemia (blood glucose 2.5 mmol/l) in nondiabetic participants
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hypoglycemia (blood glucose 2.5 mmol/l) in type 1 diabetes
Number of subjects: 32
Study: 18338960

Group type: EXPERIMENTAL
Intervention: Positive screening for PTSD
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Positive screening for depression
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: PTSD screening
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 164
Study: 16122457

Group type: EXPERIMENTAL
Intervention: Clopidogrel (n = 85)
Number of subjects: 919

Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin (both)
Number of subjects: 919

Group type: COMPARATOR
Intervention: Aspirin only (n = 598)
Number of subjects: 919

Group type: COMPARATOR
Intervention: Neither medication (n = 236)
Number of subjects: 919

Group type: COMPARATOR
Intervention: No clopidogrel (n = 834)
Number of subjects: 919
Study: 12859607

Group type: EXPERIMENTAL
Intervention: Preseason strength training programme for the hamstring muscle group with eccentric overloading, performed 1-2 times a week for 10 weeks.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no additional specific hamstring training).
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Preseason strength training programme for the hamstring muscle group with eccentric overloading.
Number of subjects: 30
Study: 10534038

Group type: EXPERIMENTAL
Intervention: Philadelphia collar on a hard wooden backboard
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Scandinavian vacuum mattress with a vacuum collar
Number of subjects: 39
Study: 8890804

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of dipyridamole
Number of subjects: 20
Study: 1985721

Group type: EXPERIMENTAL
Intervention: VAP chemotherapy (vincristine, doxorubicin, and prednisone) with radiotherapy for local relapse
Number of subjects: 98

Group type: COMPARATOR
Intervention: Triple-drug intrathecal therapy and regimens of 6-thioguanine and cytarabine alternating with vincristine, prednisone, cyclophosphamide, and cytarabine
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Treatment for testicular relapse
Number of subjects: 98
Study: 6368649

Group type: EXPERIMENTAL
Intervention: Continuous ASA treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Desensitization to ASA followed by ASA treatment
Number of subjects: 25
Study: 31328425

Group type: EXPERIMENTAL
Intervention: Cash transfer plus financial education programme
Number of subjects: 80
Study: 29952408

Group type: EXPERIMENTAL
Intervention: Total intravenous propofol anaesthesia (TIVA), n = 31
Number of subjects: 61

Group type: COMPARATOR
Intervention: Volatile induction and maintenance sevoflurane anaesthesia (VIMA), n = 30
Number of subjects: 61
Study: 26473667

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) 30 mg BID + Asunaprevir (ASV) 200 mg BID + Beclabuvir (BCV) 150 mg BID
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) + Asunaprevir (ASV) + Beclabuvir (BCV) with ribavirin
Number of subjects: 187

Group type: COMPARATOR
Intervention: Daclatasvir (DCV) + Asunaprevir (ASV) + Beclabuvir (BCV) without ribavirin
Number of subjects: 187
Study: 24446153

Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 84
Study: 22821643

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.05%
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1%
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline (sodium chloride 0.9%)
Number of subjects: 18
Study: 20374607

Group type: EXPERIMENTAL
Intervention: 6-monthly cytological screening in primary care
Number of subjects: 4439

Group type: COMPARATOR
Intervention: Referral for colposcopy
Number of subjects: 4439

Group type: EXPERIMENTAL
Intervention: HPV testing for detection of CIN2 or worse
Number of subjects: 4439

Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 4439
Study: 16926382

Group type: EXPERIMENTAL
Intervention: Maximal ADP stimulated respiration with FA-derived substrate (palmitoyl-l-carnitine + malate)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: MFO (maximal fatty acid oxidation)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: MFO during submaximal exercise at 80 W
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: MFO during submaximal exercise at 120 W
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: MFO interpolated at 35% Vo(2 peak)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: ADP sensitivity of mitochondrial respiration with FA-derived substrate
Number of subjects: 13
Study: 17663288

Group type: EXPERIMENTAL
Intervention: Cigarette smokers (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-smokers (n=50)
Number of subjects: 100
Study: 14964744

Group type: EXPERIMENTAL
Intervention: efalizumab 1.0 mg/kg/wk
Number of subjects: 1242

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1242
Study: 11179987

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) with clarithromycin
Number of subjects: 145

Group type: COMPARATOR
Intervention: Omeprazole with clarithromycin
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 145
Study: 9379635

Group type: EXPERIMENTAL
Intervention: Foldable plate-haptic silicone IOL (Chiron Adatomed, C10)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Foldable disc silicone IOL (Chiron Adatomed, 90D)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: One-piece PMMA-IOL (Pharmacia & Upjohn, 809C)
Number of subjects: 67
Study: 8472233

Group type: EXPERIMENTAL
Intervention: Plasma TFE
Number of subjects: 44

Group type: COMPARATOR
Intervention: ePTFE
Number of subjects: 44
Study: 3898805

Group type: EXPERIMENTAL
Intervention: 200 micrograms Cr3+ as chromic chloride (CrCl3)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 5 g brewer's yeast
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 11251917

Group type: EXPERIMENTAL
Intervention: Nuchal translucency (NT) measurements
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Nuchal translucency (NT) measurements expressed by MoM values
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Normative data of fetal NT thickness
Number of subjects: 879
Study: 31029436

Group type: EXPERIMENTAL
Intervention: 5HIAA levels in cerebrospinal fluid (CSF) for PE group (IELT < 1 min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 5HIAA levels in cerebrospinal fluid (CSF) for control group (IELT > 1 min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Correlation between IELT and 5HIAA levels
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of average 5HIAA levels between PE and control groups
Number of subjects: 60
Study: 30270794

Group type: EXPERIMENTAL
Intervention: Borehole drilling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Borehole rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Borehole drilling and rehabilitation
Number of subjects: 0
Study: 26895895

Group type: EXPERIMENTAL
Intervention: Closure with endoscopic clips
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-closure
Number of subjects: 28
Study: 25056981

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM)
Number of subjects: 80
Study: 22290273

Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg daily for 21 days followed by single-dose ridaforolimus 40 mg on day 14
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg daily for 14 days followed by single-dose ridaforolimus 2 mg on day 2
Number of subjects: 0
Study: 21171773

Group type: EXPERIMENTAL
Intervention: Structural Ecosystems Therapy (SET)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Health Group (HG)
Number of subjects: 67
Study: 17935597

Group type: EXPERIMENTAL
Intervention: Usual care plus memory restructuring intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 45
Study: 16022174

Group type: EXPERIMENTAL
Intervention: Two-stage adaptive design for clinical trials with survival data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coumadin Aspirin Reinfarction Study
Number of subjects: 0
Study: 12022509

Group type: EXPERIMENTAL
Intervention: Flexible parametric techniques for regression analysis using feed forward artificial neural networks (FFANNs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multilayer perceptron and radial basis function extensions of generalized linear models for survival data
Number of subjects: 0
Study: 10434166

Group type: EXPERIMENTAL
Intervention: Theophylline administration (6 mg kg‐1 infused over 7.5 min)
Number of subjects: 34